Plasma levels of free fatty acid differ in patients with left ventricular preserved, mid-range, and reduced ejection fraction

[1] Najafi F(2009)Understanding the ‘epidemic of heart failure’: a systematic review of trends in determinants of heart failure Eur J Heart Fail 11 472-479

[2] Jamrozik K(2013)2013 ACCF/AHA guideline for the management of heart failure. A report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines J Am Coll Cardiol 62 e147-e239

[3] Dobson AJ(2014)New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes Eur Heart J 35 2797-2815

[4] Yancy CW(2015)Incidence, prevalence and 1-year all-cause mortality of heart failure in Germany: a study based on electronic healthcare data of more than six million persons Clin Res Cardiol 104 688-696

[5] Jessup M(2014)Developing therapies for heart failure with preserved ejection fraction: current state and future directions JACC Heart Fail 2 97-112

[6] Bozkurt B(2005)Myocardial substrate metabolism in the normal and failing heart Physiol Rev 85 1093-1129

[7] Butler J(2009)Prognostic relevance of metabolic approach in patients with heart failure Curr Pharm Des 15 883-892

[8] Casey DE(2017)Metabolic modulators in heart disease – past, present and future Can J Cardiol 33 838-849

[9] Drazner MH(2015)Curcumin protects hearts from FFA-induced injury by activating Nrf2 and inactivating NF-κB both in vitro and in vivo J Mol Cell Cardiol 79 1-12

[10] Fonarow GC(2011)Fatty acid composition in chronic heart failure: low circulating levels of eicosatetraenoic acid and high levels of vaccenic acid are associated with disease severity and mortality J Intern Med 270 263-272

[1] Najafi F(2009)Understanding the ‘epidemic of heart failure’: a systematic review of trends in determinants of heart failure Eur J Heart Fail 11 472-479

[2] Jamrozik K(2013)2013 ACCF/AHA guideline for the management of heart failure. A report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines J Am Coll Cardiol 62 e147-e239

[3] Dobson AJ(2014)New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes Eur Heart J 35 2797-2815

[4] Yancy CW(2015)Incidence, prevalence and 1-year all-cause mortality of heart failure in Germany: a study based on electronic healthcare data of more than six million persons Clin Res Cardiol 104 688-696

[5] Jessup M(2014)Developing therapies for heart failure with preserved ejection fraction: current state and future directions JACC Heart Fail 2 97-112

[6] Bozkurt B(2005)Myocardial substrate metabolism in the normal and failing heart Physiol Rev 85 1093-1129

[7] Butler J(2009)Prognostic relevance of metabolic approach in patients with heart failure Curr Pharm Des 15 883-892

[8] Casey DE(2017)Metabolic modulators in heart disease – past, present and future Can J Cardiol 33 838-849

[9] Drazner MH(2015)Curcumin protects hearts from FFA-induced injury by activating Nrf2 and inactivating NF-κB both in vitro and in vivo J Mol Cell Cardiol 79 1-12

[10] Fonarow GC(2011)Fatty acid composition in chronic heart failure: low circulating levels of eicosatetraenoic acid and high levels of vaccenic acid are associated with disease severity and mortality J Intern Med 270 263-272